Vir Biotechnology Q3 2024 Adj EPS $(1.56) Misses $(1.05) Estimate, Sales $2.40M Miss $5.51M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology reported Q3 2024 earnings with a significant miss on both EPS and sales estimates. The company posted an EPS of $(1.56), missing the $(1.05) estimate, and sales of $2.40M, missing the $5.51M estimate. This represents a 9.06% decrease in sales compared to the same period last year.
October 31, 2024 | 8:06 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vir Biotechnology's Q3 2024 earnings report shows a significant miss on both EPS and sales estimates, with EPS at $(1.56) and sales at $2.40M. This could negatively impact the stock price in the short term.
The significant miss on both EPS and sales estimates is likely to lead to negative sentiment among investors, potentially causing a decline in the stock price. The 48.57% miss on EPS and 56.45% miss on sales are substantial, indicating potential operational or market challenges.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100